Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03254940 · ClinicalTrials.gov registry record · NA
Charge: A Text Messaging-based Weight Loss Intervention
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 534
- Enrollment target
NCT03254940: Completed NA study, sponsored by Duke University.
NCT03254940 is a NA study that has completed, run by Duke University. The registered enrollment target is 534 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03254940, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 534 participants
- Enrollment target
Study Summary
This study evaluates different versions of a text messaging-based app for weight loss. This study will place participants to 1 of 32 experimental conditions that reflect different texting components and levels. Participants will be randomized to a condition. The investigators will recruit 448 adults into a 6-month weight loss program, with an additional follow-up 6-months after the intervention ends.
Primary Outcome
Mean change in weight in kg (6 months post-randomization- baseline weight)
Interventions
- BEHAVIORAL Charge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
What the finished NCT03254940 record still lists
NCT03254940 is an interventional study that assigns participants to a tested intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Charge is the first listed.
NCT03254940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03254940 about?
NCT03254940 is a clinical study titled "Charge: A Text Messaging-based Weight Loss Intervention". This study evaluates different versions of a text messaging-based app for weight loss. This study will place participants to 1 of 32 experimental conditions that reflect different texting components and levels. Participants will be randomized to a condition. The investigators will recruit 448 adults...
What is the current status of trial NCT03254940?
This trial is currently completed. It is a NA study. The enrollment target is 534 participants. The study started on 2018-01-31. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT03254940?
The interventions under investigation include: Charge (BEHAVIORAL).
Who is sponsoring clinical trial NCT03254940?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03254940's enrollment target sits among peer trials
534 188th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI